000700MPTSZSE

Jiangnan Mould and Plastic Technology Co., Ltd.

模塑科技

000700

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryAutomobile Manufacturing
ISINCNE0000000N5
ListedFebruary 28, 1997
Websitewww.000700.com
IR Emailscy@000700.com
Phone(+86)510-86242802
Sourcecninfo.com.cn
AddressNo. 8, Changqing Road, Zhouzhuang Town, Jiangyin, Jiangsu

Company Overview

Jiangnan Mould and Plastic Technology Co., Ltd. (JNMPT) is a manufacturing company based in Zhouzhuang, Jiangyin, Jiangsu Province, specializing in the development, manufacture, and sales of automotive spare parts. Founded in June 1988 and listed on the Shenzhen Stock Exchange in February 1997, JNMPT primarily produces bumpers, plastic products, moulds, and high-tech mould and plastic products. The company has positioned itself as one of the largest suppliers of automotive exterior spare parts in China. JNMPT operates multiple production bases across China, including locations in Wuxi, Shanghai, Shenyang, Wuhan, and Yantai, as well as facilities in Mexico, supporting its strategy for global market expansion. The company serves a range of well-known automotive brands such as BMW Brilliance, Jaguar Land Rover, and Beijing Hyundai. In addition to its automotive business, JNMPT has invested in the health care sector through the Wuxi Mingci Cardiovascular Hospital, which specializes in cardiovascular and diabetes care, collaborating with international medical institutions to enhance service quality.

AI-generated from company disclosures and CNInfo data.

Company Profile

1. JNMPT, the leading automotive exterior spare parts supplier of mid-end and high-end joint venture brands, who are comparably stable in China right now. The operation bases of JNMPT are located in North-East China, Beijing- Tianjing District, Yangtze River Delta and Middle China with leading market proportion , strong advantage of regional coverage and industry scale. Meanwhile, at the invitation of BMW, the company has established two new plants in Mexico and USA , which is the first step for the globalized strategy and the overseas market exploitation. 2. Cooperating with CARDIOLOGISTS&PARTNERS MEDICAL GROUP and HDZ, specialized in cardiovascular and diabetes disease, Wuxi Mingci can provide the patient with the international experts, exquisite technology and first-rate service.

57 announcements tracked· Last: September 21, 2026

Key Financials

As of 2026-10-03T00:00:00.000+00:00
Revenue¥3.05bn
Net Profit¥315.0M
ROE7.60%
Debt Ratio42.65%
Monetary Funds¥1.01bn
Receivables¥1.07bn
Total Shares918.0M

Announcements

57 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.